Kidney Drug Shows Promise for 800 Million Patients

For the 800 million people living with chronic kidney disease worldwide, a drug trial just delivered news that could change everything.

Researchers found that finerenone, previously used only for diabetic kidney disease, also protects kidney function in patients without diabetes. The discovery could expand treatment options for more than half of all kidney disease patients who currently have limited choices.

The international FIND-CKD trial followed 1,584 adults with chronic kidney disease but no diabetes for just over three years. All participants had reduced kidney function and elevated protein in their urine, both signs of ongoing kidney damage.

Led by clinical pharmacologist Hiddo Lambers Heerspink at the University Medical Center Groningen, the study tested whether finerenone could slow the silent progression of a disease that often causes no symptoms until serious damage occurs. Patients received either the drug or a placebo alongside standard medications.

The results were striking. Finerenone significantly slowed the decline in how effectively kidneys filtered blood over 2.5 years. Patients taking the drug also saw a 23 percent reduction in major kidney complications, heart failure hospitalizations, and cardiovascular death compared to those on placebo.

Even more encouraging, protein levels in urine dropped by over 41 percent in the finerenone group after just six months, compared to only 9 percent with placebo. More than half of patients achieved at least a 30 percent reduction, an important indicator of better kidney health ahead.

The Ripple Effect

The implications extend far beyond individual patients. Chronic kidney disease ranks among the leading causes of kidney failure, heart complications, and early death worldwide. Yet for non-diabetic patients who make up more than half of those affected, treatment guidelines offer few options.

This study opens the door for millions of people previously left with limited ways to slow their disease. The drug proved both effective and safe in this population, offering what Lambers Heerspink calls "a clear delay in the decline of kidney function on top of current standard care."

Physicians now have new therapeutic options to help preserve kidney function and reduce complications in a broad, underserved patient population. The findings, published in the New England Journal of Medicine, represent a major step forward for kidney disease care.

For patients watching their kidney function slowly decline, this research brings something powerful: a proven way to slow the disease and reduce life-threatening complications.